Harbin Pharmaceutical Group (600664.SH): Ceftizoxime Sodium for Injection Passes Generic Drug Consistency Evaluation

Harbin Pharmaceutical Group (600664.SH) announced that recently, its subsidiary Harbin Pharmaceutical Group General Pharmaceutical Factory ("HPGC General Factory") received the Drug Supplementary Application Approval Notices issued by the National Medical Products Administration for Ceftizoxime Sodium for Injection [0.5g (calculated as C13H13N5O5S2), Notice No.: 2026B07860; 1.0g (calculated as C13H13N5O5S2), Notice No.: 2026B07866]. The above drugs have passed the generic drug quality and efficacy consistency evaluation. Ceftizoxime Sodium for Injection is indicated for lower respiratory tract infections, urinary tract infections, intra-abdominal infections, pelvic infections, septicemia, skin and soft tissue infections, bone and joint infections, meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae, and uncomplicated gonorrhea caused by susceptible bacteria.